Progress in Diabetic Retinopathy in the Spotlight at ASRS
Wednesday, August 09, 2017 | Medical Studies
Treatments for diabetic retinopathy with new mechanisms of action and new options for age-related macular degeneration will be garnering attention here at the American Society of Retina Specialists (ASRS) 2017 Annual Meeting, according to a report in Medscape.
Although current antivascular endothelial growth-factor (VEGF) treatments have proved effective, the frequent intravitreal injections required impose a severe burden on patients, said Pravin Dugel, MD, chair of the ASRS health economics committee.
"In diabetic retinopathy and macular edema, the goal is to improve efficacy and durability by modifying the disease with drugs instead of lasers," Dr Dugel told Medscape Medical News.